https://atuka.com/ 2026-03-16T15:11:27+00:00 https://atuka.com/collaborations/ 2025-08-06T18:02:08+00:00 https://atuka.com/non-human-primate-services/ 2025-05-07T19:57:31+00:00 https://atuka.com/scientific-leadership/ 2025-07-24T12:06:13+00:00 https://atuka.com/contact/ 2026-03-26T20:43:43+00:00 https://atuka.com/research-milestones/ 2025-07-24T12:06:27+00:00 https://atuka.com/atuka-company-overview/ 2025-07-07T16:38:09+00:00 https://atuka.com/gene-therapy/ 2025-07-08T14:40:47+00:00 https://atuka.com/parkinsons-disease-models/ 2026-03-26T20:48:40+00:00 https://atuka.com/careers-2/ 2024-10-03T14:04:54+00:00 https://atuka.com/services/ 2026-03-26T20:49:36+00:00 https://atuka.com/news-and-insights/ 2026-03-26T20:50:15+00:00 https://atuka.com/careers/ 2025-12-02T13:13:36+00:00 https://atuka.com/about/ 2026-03-26T20:46:29+00:00 https://atuka.com/our-science/ 2026-03-26T20:47:52+00:00 https://atuka.com/privacy-policy/ 2025-07-24T12:06:42+00:00 https://atuka.com/for-anna-oliinyk-helping-to-develop-better-treatments-for-parkinsons-is-personal/ 2026-03-16T16:02:36+00:00 https://atuka.com/alan-stratton-on-assisting-companies-through-transformation/ 2026-01-08T17:30:15+00:00 https://atuka.com/the-importance-of-data-management-in-ensuring-the-integrity-of-biomedical-research/ 2025-12-11T15:41:57+00:00 https://atuka.com/towards-a-cure-through-collaboration-and-clarity-perspectives-from-the-2025-mjff-therapeutics-conference/ 2025-12-09T14:44:21+00:00 https://atuka.com/a-quality-system-that-boosts-both-research-integrity-and-innovation/ 2025-12-10T17:16:28+00:00 https://atuka.com/paper/discovery-series-2-bdnf-trkb/ 2025-11-07T15:21:15+00:00 https://atuka.com/sahar-tamadon-on-her-passion-for-neuroscience/ 2025-10-21T16:02:59+00:00 https://atuka.com/how-a-backyard-mishap-put-tom-johnston-on-his-unexpected-path-to-neuroscience/ 2025-10-15T14:51:35+00:00 https://atuka.com/better-data-better-reproducibility-the-importance-of-quality-systems/ 2025-12-10T17:16:54+00:00 https://atuka.com/service/anxiety-assessment-using-the-human-intruder-test-hit/ 2025-08-27T18:10:49+00:00 https://atuka.com/vidya-alexander-on-the-human-brain-and-the-endless-possibilities-for-discovery/ 2025-10-14T18:13:45+00:00 https://atuka.com/resource/a-brain-shuttled-antibody-targeting-alpha-synuclein-aggregates-for-the-treatment-of-synucleinopathies/ 2025-09-17T20:46:06+00:00 https://atuka.com/paper/redefining-parkinsons-disease-biological-classification-and-the-future-of-therapeutics/ 2025-07-30T13:57:05+00:00 https://atuka.com/model/biodistribution-in-rodent-and-non-human-primate/ 2025-09-17T20:46:44+00:00 https://atuka.com/listening-to-patients-leading-with-science/ 2025-10-14T23:56:28+00:00 https://atuka.com/model/pff-%ce%b1-synuclein-over-expressing-rodent/ 2025-07-07T15:55:32+00:00 https://atuka.com/model/bilateral-aav-%ce%b1-synuclein-over-expressing-rodent/ 2026-03-23T18:32:07+00:00 https://atuka.com/model/aav-%ce%b1-synuclein-overexpressing-non-human-primate/ 2026-03-05T22:21:09+00:00 https://atuka.com/model/aav-alpha-synuclein-over-expressing-rodent/ 2026-03-23T18:31:17+00:00 https://atuka.com/model/cognition/ 2025-08-28T17:40:13+00:00 https://atuka.com/model/primate-model-of-dyskinesia/ 2026-03-05T22:18:16+00:00 https://atuka.com/model/bilateral-6-ohda-lesioned-rat-2/ 2026-03-23T18:38:36+00:00 https://atuka.com/model/mptp-lesioned-non-human-primate/ 2026-03-05T22:17:12+00:00 https://atuka.com/model/unilateral-6-ohda-lesioned-rodent/ 2026-03-23T18:39:58+00:00 https://atuka.com/model/mptp-lesioned-mouse/ 2026-03-23T18:32:40+00:00 https://atuka.com/gregory-lops-on-blending-creative-vision-with-lab-precision/ 2025-10-14T23:07:35+00:00 https://atuka.com/atuka-moves-in-to-north-americas-largest-urban-innovation-hub/ 2025-10-14T23:42:44+00:00 https://atuka.com/paper/discovery-series-1-d1-pam/ 2025-03-26T16:30:52+00:00 https://atuka.com/expanding-frontiers-in-neuroimmunology/ 2025-10-14T23:57:20+00:00 https://atuka.com/how-ai-could-help-dramatically-change-the-drug-discovery-process/ 2025-10-14T23:45:28+00:00 https://atuka.com/resource/low-%ce%b2-predicts-motor-output-and-cell-degeneration-in-the-a53t-parkinsons-disease-rat-model/ 2025-02-18T12:00:00+00:00 https://atuka.com/how-andrea-datu-sets-up-her-teammates-for-success/ 2025-10-14T23:08:20+00:00 https://atuka.com/tielli-magnus-on-the-sources-of-her-scientific-inspiration/ 2025-10-14T23:08:59+00:00 https://atuka.com/embracing-a-culture-of-continuous-learning/ 2025-10-14T23:10:09+00:00 https://atuka.com/resource/deep-brain-stimulation-halts-parkinsons-disease-related-immune-dysregulation-in-the-brain-and-peripheral-blood/ 2025-01-01T12:00:00+00:00 https://atuka.com/paper/optimizing-preclinical-studies-for-parkinsons-disease-therapeutics/ 2024-12-17T14:39:26+00:00 https://atuka.com/parkinsons-disease-prevalence-is-soaring-but-is-there-a-good-news-story-hidden-in-the-data/ 2025-10-07T15:40:22+00:00 https://atuka.com/highlights-from-neuroscience-2024-advances-in-parkinsons-disease-research/ 2024-11-08T14:35:32+00:00 https://atuka.com/new-frontiers-in-inflammasome-therapeutics-insights-from-the-6th-annual-summit/ 2025-10-07T15:44:26+00:00 https://atuka.com/atuka-releases-its-latest-white-paper-on-the-future-of-gene-therapy/ 2025-10-14T23:31:01+00:00 https://atuka.com/paper/the-future-of-gene-therapy/ 2024-10-11T14:47:19+00:00 https://atuka.com/announcing-a-1-5m-collaboration-with-kannalife-sciences-and-the-michael-j-fox-foundation/ 2025-10-14T23:26:49+00:00 https://atuka.com/what-the-market-overlooked-in-seeloss-recent-trehalose-study/ 2024-07-30T23:42:42+00:00 https://atuka.com/atuka-welcomes-new-board-member-ian-lennox/ 2024-09-30T19:37:12+00:00 https://atuka.com/tavapodon-offers-great-promise-as-a-new-therapeutic-for-parkinsons-disease/ 2024-09-30T19:38:14+00:00 https://atuka.com/resource/using-artificial-intelligence-to-identify-drugs-for-repurposing-to-treat-l-dopa-induced-dyskinesia/ 2024-05-01T12:00:00+00:00 https://atuka.com/resource/enhanced-firing-of-locus-coeruleus-neurons-and-sk-channel-dysfunction-are-conserved-in-distinct-models-of-prodromal-parkinsons-disease-2/ 2024-01-31T12:00:00+00:00 https://atuka.com/resource/brain-to-gut-trafficking-of-alpha-synuclein-by-cd11c-cells-in-a-mouse-model-of-parkinsons-disease/ 2023-11-20T12:00:00+00:00 https://atuka.com/resource/inflammasome-inhibition-protects-dopaminergic-neurons-from-%ce%b1-synuclein-pathology-in-a-model-of-progressive-parkinsons-disease/ 2023-03-21T12:00:00+00:00 https://atuka.com/resource/alterations-in-the-lrrk2-rab-pathway-in-urinary-extracellular-vesicles-as-parkinsons-disease-and-pharmacodynamic-biomarkers/ 2023-02-07T12:00:00+00:00 https://atuka.com/resource/expansion-of-regulatory-t-cells-by-cd28-superagonistic-antibodies-attenuates-neurodegeneration-in-a53t-%ce%b1-synuclein-parkinsons-disease-mice/ 2022-12-31T12:00:00+00:00 https://atuka.com/resource/temporal-spatial-and-molecular-pattern-of-dopaminergic-neurodegeneration-in-the-aav-a53t-%ce%b1-synuclein-rat-model-of-parkinsons-disease/ 2022-08-01T12:00:00+00:00 https://atuka.com/resource/toward-in-vivo-proof-of-binding-of-18f-labeled-inhibitor-18ftrack-to-peripheral-tropomyosin-receptor-kinases/ 2022-07-30T12:00:00+00:00 https://atuka.com/resource/special-issue-on-new-therapeutic-approaches-to-parkinson-disease/ 2022-05-01T12:00:00+00:00 https://atuka.com/resource/p2b001-extended-release-pramipexole-and-rasagiline-a-new-treatment-option-in-development-for-parkinsons-disease/ 2022-03-10T12:00:00+00:00 https://atuka.com/resource/neurodegeneration-by-%ce%b1-synuclein-specific-t-cells-in-aav-a53t-%ce%b1-synuclein-parkinsons-disease-mice/ 2022-03-01T12:00:00+00:00 https://atuka.com/resource/enhanced-firing-of-locus-coeruleus-neurons-and-sk-channel-dysfunction-are-conserved-in-distinct-models-of-prodromal-parkinsons-disease/ 2022-02-24T12:00:00+00:00 https://atuka.com/resource/%ce%b1-synuclein-induced-kv4-channelopathy-in-mouse-vagal-motoneurons-drives-nonmotor-parkinsonian-symptoms/ 2021-03-12T12:00:00+00:00 https://atuka.com/resource/a-novel-dopamine-d3r-agonist-sk609-with-norepinephrine-transporter-inhibition-promotes-improvement-in-cognitive-task-performance-in-rodent-and-non-human-primate-models-of-parkinsons-disease/ 2021-01-01T12:00:00+00:00 https://atuka.com/resource/exosome-markers-of-lrrk2-kinase-inhibition/ 2020-11-13T12:00:00+00:00 https://atuka.com/resource/the-selective-5-ht1a-receptor-agonist-nlx-112-exerts-anti-dyskinetic-effects-in-mptp-treated-macaques/ 2020-09-01T12:00:00+00:00 https://atuka.com/resource/the-promise-and-challenges-of-developing-mirna-based-therapeutics-for-parkinsons-disease/ 2020-03-31T12:00:00+00:00 https://atuka.com/resource/early-onset-impairment-of-the-ubiquitin-proteasome-system-in-dopaminergic-neurons-caused-by-%ce%b1-synuclein/ 2020-02-14T12:00:00+00:00 https://atuka.com/resource/nyx%e2%80%90458-improves-cognitive-performance-in-a-primate-parkinsons-disease-model/ 2020-01-22T12:00:00+00:00 https://atuka.com/resource/gm1-ganglioside-modifies-%ce%b1-synuclein-toxicity-and-is-neuroprotective-in-a-rat-%ce%b1-synuclein-model-of-parkinsons-disease/ 2019-06-10T12:00:00+00:00 https://atuka.com/resource/beneficial-effects-of-trehalose-on-striatal-dopaminergic-deficits-in-rodent-and-primate-models-of-synucleinopathy-in-parkinsons-disease/ 2019-03-27T12:00:00+00:00 https://atuka.com/resource/repurposing-drugs-to-treat-l-dopa-induced-dyskinesia-in-parkinsons-disease/ 2019-03-01T12:00:00+00:00 https://atuka.com/resource/pridopidine-a-clinic%e2%80%90ready-compound-reduces-34%e2%80%90dihydroxyphenylalanine%e2%80%90induced-dyskinesia-in-parkinsonian-macaques/ 2018-12-21T12:00:00+00:00 https://atuka.com/resource/viewpoint-developing-drugs-for-levodopa%e2%80%90induced-dyskinesia-in-pd-lessons-learnt-what-does-the-future-hold/ 2018-11-15T12:00:00+00:00 https://atuka.com/resource/pharmacokinetic-pharmacodynamic-correlation-analysis-of-amantadine-for-levodopa-induced-dyskinesia/ 2018-08-07T12:00:00+00:00 https://atuka.com/resource/corrigendum-to-sirtuin-3-rescues-neurons-through-the-stabilisation-of-mitochondrial-biogenetics-in-the-virally-expressing-mutant-%ce%b1-synuclein-rat-model-of-parkinsonism-neurobiol/ 2018-08-01T12:00:00+00:00 https://atuka.com/resource/a53t-%ce%b1-synuclein-overexpression-in-murine-locus-coeruleus-induces-parkinsons-disease-like-pathology-in-neurons-and-glia/ 2018-05-10T12:00:00+00:00 https://atuka.com/resource/non-steric-zipper-models-for-pathogenic-%ce%b1-synuclein-conformers/ 2018-05-01T12:00:00+00:00 https://atuka.com/resource/dpi-289-a-novel-mixed-delta-opioid-agonist-mu-opioid-antagonist-dama-has-l-dopa-sparing-potential-in-parkinsons-disease/ 2018-03-01T12:00:00+00:00 https://atuka.com/resource/reply-to-can-stn-dbs-protect-both-nigral-somata-and-innervation-of-the-striatum/ 2017-10-26T12:00:00+00:00 https://atuka.com/resource/sirtuin-3-rescues-neurons-through-the-stabilisation-of-mitochondrial-biogenetics-in-the-virally-expressing-mutant-%ce%b1-synuclein-rat-model-of-parkinsonism/ 2017-10-01T12:00:00+00:00 https://atuka.com/resource/animal-models-of-%ce%b1-synucleinopathy-for-parkinson-disease-drug-development/ 2017-07-13T12:00:00+00:00 https://atuka.com/resource/subthalamic-nucleus-deep-brain-stimulation-is-neuroprotective-in-the-a53t-%ce%b1%e2%80%90synuclein-parkinsons-disease-rat-model/ 2017-06-01T12:00:00+00:00 https://atuka.com/resource/aav1-2-induced-overexpression-of-a53t-%ce%b1-synuclein-in-the-substantia-nigra-results-in-degeneration-of-the-nigrostriatal-system-with-lewy-like-pathology-and-motor-impairment-a-new-mouse-model-for/ 2017-02-01T12:00:00+00:00 https://atuka.com/resource/towards-a-non-human-primate-model-of-alpha-synucleinopathy-for-development-of-therapeutics-for-parkinsons-disease-optimization-of-aav1-2-delivery-parameters-to-drive-sustained-expression-of/ 2016-11-30T12:00:00+00:00 https://atuka.com/resource/%ce%b1-synuclein-based-animal-models-of-parkinsons-disease-challenges-and-opportunities-in-a-new-era/ 2016-11-01T12:00:00+00:00 https://atuka.com/resource/tor1a-mice-develop-dystonia-like-movements-via-a-striatal-dopaminergic-dysregulation-triggered-by-peripheral-nerve-injury/ 2016-10-03T12:00:00+00:00 https://atuka.com/resource/dopamine-reuptake-inhibitors-in-parkinsons-disease-a-review-of-nonhuman-primate-studies-and-clinical-trials/ 2016-04-13T12:00:00+00:00 https://atuka.com/resource/the-highly-selective-5-ht1a-agonist-f15599-reduces-l-dopa-induced-dyskinesia-without-compromising-anti-parkinsonian-benefits-in-the-mptp-lesioned-macaque/ 2015-10-01T12:00:00+00:00 https://atuka.com/resource/the-link-between-mitochondrial-complex-i-and-brain-derived-neurotrophic-factor-in-sh-sy5y-cells-the-potential-of-jnx1001-as-a-therapeutic-agent/ 2015-10-01T12:00:00+00:00 https://atuka.com/resource/reproducibility-of-a-parkinsonism-related-metabolic-brain-network-in-non-human-primates-a-descriptive-pilot-study-with-fdg-pet/ 2015-08-01T12:00:00+00:00 https://atuka.com/resource/treatment-with-trehalose-prevents-behavioral-and-neurochemical-deficits-produced-in-an-aav-%ce%b1-synuclein-rat-model-of-parkinsons-disease/ 2015-05-14T12:00:00+00:00 https://atuka.com/resource/gap-junction-blockers-attenuate-beta-oscillations-and-improve-forelimb-function-in-hemiparkinsonian-rats/ 2015-03-01T12:00:00+00:00 https://atuka.com/resource/l-745870-reduces-the-expression-of-abnormal-involuntary-movements-in-the-6-ohda-lesioned-rat/ 2015-02-01T12:00:00+00:00 https://atuka.com/resource/management-of-impulse-control-disorders-in-parkinsons-disease-controversies-and-future-approaches/ 2015-01-21T12:00:00+00:00 https://atuka.com/resource/pioglitazone-may-impair-l%e2%80%90dopa-anti%e2%80%90parkinsonian-efficacy-in-the-mptp%e2%80%90lesioned-macaque-results-of-a-pilot-study/ 2015-01-20T12:00:00+00:00 https://atuka.com/resource/monoamine-reuptake-inhibitors-in-parkinsons-disease/ 2015-01-01T12:00:00+00:00 https://atuka.com/resource/selective-loss-of-bi-directional-synaptic-plasticity-in-the-direct-and-indirect-striatal-output-pathways-accompanies-generation-of-parkinsonism-and-l-dopa-induced-dyskinesia-in-mouse-models/ 2014-11-01T12:00:00+00:00 https://atuka.com/resource/uwa-121-a-mixed-dopamine-and-serotonin-re-uptake-inhibitor-enhances-l-dopa-anti-parkinsonian-action-without-worsening-dyskinesia-or-psychosis-like-behaviours-in-the-mptp-lesioned-common-marmoset/ 2014-07-01T12:00:00+00:00 https://atuka.com/resource/the-opioid-system-in-levodopa-induced-dyskinesia/ 2014-01-01T12:00:00+00:00 https://atuka.com/resource/symptomatic-models-of-parkinsons-disease-and-l-dopa-induced-dyskinesia-in-non-human-primates/ 2014-01-01T12:00:00+00:00 https://atuka.com/resource/tc-8831-a-nicotinic-acetylcholine-receptor-agonist-reduces-l-dopa-induced-dyskinesia-in-the-mptp-macaque/ 2013-10-01T12:00:00+00:00 https://atuka.com/resource/rotigotine-polyoxazoline-conjugate-ser%e2%80%90214-provides-robust-and-sustained-antiparkinsonian-benefit/ 2013-09-03T12:00:00+00:00 https://atuka.com/resource/the-effects-of-fast-off-d2-receptor-antagonism-on-l-dopa-induced-dyskinesia-and-psychosis-in-parkinsonian-macaques/ 2013-06-01T12:00:00+00:00 https://atuka.com/resource/alternating-hemiplegia-of-childhood-related-neural-and-behavioural-phenotypes-in-nak-atpase-%ce%b13-missense-mutant-mice/ 2013-03-20T12:00:00+00:00 https://atuka.com/resource/rgfp109-a-histone-deacetylase-inhibitor-attenuates-l-dopa-induced-dyskinesia-in-the-mptp-lesioned-marmoset-a-proof-of-concept-study/ 2013-02-01T12:00:00+00:00 https://atuka.com/resource/deep-brain-stimulation-of-the-substantia-nigra-pars-reticulata-improves-forelimb-akinesia-in-the-hemiparkinsonian-rat/ 2013-01-15T12:00:00+00:00 https://atuka.com/resource/use-of-catechol%e2%80%90o%e2%80%90methyltransferase-inhibition-to-minimize-l%e2%80%9034%e2%80%90dihydroxyphenylalanine%e2%80%90induced-dyskinesia-in-the-1%e2%80%90methyl%e2%80%904%e2%80%90phenyl/ 2013-01-03T12:00:00+00:00 https://atuka.com/resource/the-pharmacology-of-l-dopa-induced-dyskinesia-in-parkinsons-disease/ 2013-01-01T12:00:00+00:00 https://atuka.com/resource/novel-nondopaminergic-targets-for-motor-features-of-parkinsons-disease-review-of-recent-trials/ 2012-12-05T12:00:00+00:00 https://atuka.com/resource/elevated-potassium-provides-an-ionic-mechanism-for-deep-brain-stimulation-in-the-hemiparkinsonian-rat/ 2012-11-04T12:00:00+00:00 https://atuka.com/resource/selective-preservation-of-mecp2-in-catecholaminergic-cells-is-sufficient-to-improve-the-behavioral-phenotype-of-male-and-female-mecp2-deficient-mice/ 2012-10-16T12:00:00+00:00 https://atuka.com/resource/l-dopa-pharmacokinetics-in-the-mptp-lesioned-macaque-model-of-parkinsons-disease/ 2012-10-01T12:00:00+00:00 https://atuka.com/resource/the-monoamine-re-uptake-inhibitor-uwa-101-improves-motor-fluctuations-in-the-mptp-lesioned-common-marmoset/ 2012-09-20T12:00:00+00:00 https://atuka.com/resource/a-critique-of-available-scales-and-presentation-of-the-non%e2%80%90human-primate-dyskinesia-rating-scale/ 2012-09-13T12:00:00+00:00 https://atuka.com/resource/l-745870-reduces-l-dopa-induced-dyskinesia-in-the-1-methyl-4-phenyl-1236-tetrahydropyridine-lesioned-macaque-model-of-parkinsons-disease/ 2012-05-22T12:00:00+00:00 https://atuka.com/resource/l-745870-reduces-l-dopa-induced-dyskinesia-in-the-1-methyl-4-phenyl-1236-tetrahydropyridine-lesioned-macaque-model-of-parkinsons-disease-2/ 2012-05-22T12:00:00+00:00 https://atuka.com/resource/increased-levels-of-5%e2%80%90ht1a-receptor-binding-in-ventral-visual-pathways-in-parkinsons-disease/ 2012-03-14T12:00:00+00:00 https://atuka.com/resource/dihydropyridine-calcium-channel-blockers-and-the-progression-of-parkinsonism/ 2012-03-01T12:00:00+00:00 https://atuka.com/resource/a-novel-mdma-analogue-uwa%e2%80%90101-that-lacks-psychoactivity-and-cytotoxicity-enhances-l-%e2%80%90dopa-benefit-in-parkinsonian-primates/ 2012-02-17T12:00:00+00:00 https://atuka.com/resource/5-ht2a-receptor-levels-increase-in-mptp-lesioned-macaques-treated-chronically-with-l-dopa/ 2012-01-01T12:00:00+00:00 https://atuka.com/resource/regulation-of-cortical-and-striatal-5-ht1a-receptors-in-the-mptp-lesioned-macaque/ 2012-01-01T12:00:00+00:00 https://atuka.com/resource/5-ht1a-receptor-stimulation-and-l-dopa-induced-dyskinesia-in-parkinsons-disease-bridging-the-gap-between-serotonergic-and-glutamatergic-mechanisms/ 2011-10-01T12:00:00+00:00 https://atuka.com/resource/the-serotonergic-system-in-parkinsons-disease/ 2011-10-01T12:00:00+00:00 https://atuka.com/resource/anatomically-selective-serotonergic-type-1a-and-serotonergic-type-2a-therapies-for-parkinsons-disease-an-approach-to-reducing-dyskinesia-without-exacerbating-parkinsonism/ 2011-07-22T12:00:00+00:00 https://atuka.com/resource/anatomically-selective-serotonergic-type-1a-and-serotonergic-type-2a-therapies-for-parkinsons-disease-an-approach-to-reducing-dyskinesia-without-exacerbating-parkinsonism-2/ 2011-07-22T12:00:00+00:00 https://atuka.com/resource/pros-and-cons-of-a-prion-like-pathogenesis-in-parkinsons-disease/ 2011-06-20T12:00:00+00:00 https://atuka.com/resource/a-proof%e2%80%90of%e2%80%90concept-randomized-placebo%e2%80%90controlled-multiple-cross%e2%80%90overs-n%e2%80%90of%e2%80%901-study-of-naftazone-in-parkinsons-disease/ 2011-05-18T12:00:00+00:00 https://atuka.com/resource/changes-in-the-mrna-levels-of-%ce%b12a-and-%ce%b12c-adrenergic-receptors-in-rat-models-of-parkinsons-disease-and-l-dopa-induced-dyskinesia/ 2011-05-12T12:00:00+00:00 https://atuka.com/resource/characterization-of-34-methylenedioxymethamphetamine-mdma-enantiomersin-vitroand-in-the-mptp-lesioned-primater-mdma-reduces-severity-of-dyskinesia-whereass-mdma-extends-duration-of-on-time/ 2011-05-11T12:00:00+00:00 https://atuka.com/resource/the-selective-mu%e2%80%90opioid-receptor-antagonist-adl5510-reduces-levodopa%e2%80%90induced-dyskinesia-without-affecting-antiparkinsonian-action-in-mptp%e2%80%90lesioned-macaque-model-of-parkinsons/ 2011-04-04T12:00:00+00:00 https://atuka.com/resource/generation-of-a-model-of-l-dopa-induced-dyskinesia-in-two-different-mouse-strains/ 2011-04-01T12:00:00+00:00 https://atuka.com/resource/progressive-neurodegeneration-or-endogenous-compensation-in-an-animal-model-of-parkinsons-disease-produced-by-decreasing-doses-of-alpha-synuclein/ 2011-03-07T12:00:00+00:00 https://atuka.com/resource/altered-function-of-glutamatergic-cortico-striatal-synapses-causes-output-pathway-abnormalities-in-a-chronic-model-of-parkinsonism/ 2011-03-01T12:00:00+00:00 https://atuka.com/resource/new-approaches-to-therapy/ 2011-01-01T12:00:00+00:00 https://atuka.com/resource/fatty-acid-amide-hydrolase-faah-inhibition-reduces-l-34-dihydroxyphenylalanine-induced-hyperactivity-in-the-1-methyl-4-phenyl-1236-tetrahydropyridine-lesioned-non-human-primate-model-of-parkinso/ 2010-10-21T12:00:00+00:00 https://atuka.com/resource/fatty-acid-amide-hydrolase-faah-inhibition-reduces-l-34-dihydroxyphenylalanine-induced-hyperactivity-in-the-1-methyl-4-phenyl-1236-tetrahydropyridine-lesioned-non-human-primate-model-of-parkinso-2/ 2010-10-21T12:00:00+00:00 https://atuka.com/resource/the-%ce%b12-adrenergic-antagonist-fipamezole-improves-quality-of-levodopa-action-in-parkinsonian-primates/ 2010-09-07T12:00:00+00:00 https://atuka.com/resource/locomotor-response-to-l-dopa-in-reserpine-treated-rats-following-central-inhibition-of-aromatic-l-amino-acid-decarboxylase-further-evidence-for-non-dopaminergic-actions-of-l-dopa-and-its-metabolites/ 2010-09-01T12:00:00+00:00 https://atuka.com/resource/effect-of-histamine-h2-receptor-antagonism-on-levodopa-induced-dyskinesia-in-the-mptp%e2%80%90macaque-model-of-parkinsons-disease/ 2010-07-23T12:00:00+00:00 https://atuka.com/resource/increased-5%e2%80%90ht2a-receptors-in-the-temporal-cortex-of-parkinsonian-patients-with-visual-hallucinations/ 2010-07-23T12:00:00+00:00 https://atuka.com/resource/binding-of-dopamine-and-3-methoxytyramine-as-l-dopa-metabolites-to-human-%ce%b12-adrenergic-and-dopaminergic-receptors/ 2010-07-01T12:00:00+00:00 https://atuka.com/resource/antidyskinetic-actions-of-amantadine-in-parkinsons-disease-are-benefits-maintained-in-the-long-term/ 2010-06-01T12:00:00+00:00 https://atuka.com/resource/reduction-of-l-dopa-induced-dyskinesia-by-the-selective-metabotropic-glutamate-receptor-5-antagonist-3-2-methyl-13-thiazol-4-ylethynylpyridine-in-the-1-methyl-4-phenyl-1236-tetrahydropyridine/ 2010-03-15T12:00:00+00:00 https://atuka.com/resource/reduction-of-l-dopa-induced-dyskinesia-by-the-selective-metabotropic-glutamate-receptor-5-antagonist-3-2-methyl-13-thiazol-4-ylethynylpyridine-in-the-1-methyl-4-phenyl-1236-tetrahydropyridine-2/ 2010-03-15T12:00:00+00:00 https://atuka.com/resource/the-mptp-lesioned-non-human-primate-models-of-parkinsons-disease-past-present-and-future/ 2010-01-01T12:00:00+00:00 https://atuka.com/resource/expression-of-human-a53t-alpha-synuclein-in-the-rat-substantia-nigra-using-a-novel-aav1-2-vector-produces-a-rapidly-evolving-pathology-with-protein-aggregation-dystrophic-neurite-architecture-and-nig/ 2010-01-01T12:00:00+00:00 https://atuka.com/resource/neuropsychiatric-behaviors-in-the-mptp-marmoset-model-of-parkinsons-disease/ 2010-01-01T12:00:00+00:00 https://atuka.com/resource/physical-and-crystallographic-characterisation-of-the-mglu5-antagonist-mtep-and-its-monohydrochloride/ 2010-01-01T12:00:00+00:00 https://atuka.com/resource/synaptic-recruitment-of-ampa-glutamate-receptor-subunits-in-levodopa%e2%80%90induced-dyskinesia-in-the-mptp%e2%80%90lesioned-nonhuman-primate/ 2009-10-22T12:00:00+00:00 https://atuka.com/resource/dopamine-d3-receptor-stimulation-underlies-the-development-of-l-dopa-induced-dyskinesia-in-animal-models-of-parkinsons-disease/ 2009-08-01T12:00:00+00:00 https://atuka.com/resource/new-insights-into-the-organization-of-the-basal-ganglia/ 2009-06-09T12:00:00+00:00 https://atuka.com/resource/serotonin-and-parkinsons-disease-on-movement-mood-and-madness/ 2009-05-01T12:00:00+00:00 https://atuka.com/resource/mechanisms-compensating-for-dopamine-loss-in-early-parkinson-disease/ 2009-02-17T12:00:00+00:00 https://atuka.com/resource/%ce%b11-adrenoceptors-mediate-dihydroxyphenylalanine-induced-activity-in-1-methyl-4-phenyl-1236-tetrahydropyridine-lesioned-macaques/ 2008-10-27T12:00:00+00:00 https://atuka.com/resource/%ce%b11-adrenoceptors-mediate-dihydroxyphenylalanine-induced-activity-in-1-methyl-4-phenyl-1236-tetrahydropyridine-lesioned-macaques-2/ 2008-10-27T12:00:00+00:00 https://atuka.com/resource/the-nociceptin-orphanin-fq-nop-receptor-antagonist-j%e2%80%90113397-enhances-the-effects-of-levodopa-in-the-mptp%e2%80%90lesioned-nonhuman-primate-model-of-parkinsons-disease/ 2008-10-15T12:00:00+00:00 https://atuka.com/resource/non-dopaminergic-treatments-in-development-for-parkinsons-disease/ 2008-10-01T12:00:00+00:00 https://atuka.com/resource/functional-interaction-between-adenosine-a2a-and-group-iii-metabotropic-glutamate-receptors-to-reduce-parkinsonian-symptoms-in-rats/ 2008-09-01T12:00:00+00:00 https://atuka.com/resource/dietary-resveratrol-administration-increases-mnsod-expression-and-activity-in-mouse-brain/ 2008-07-01T12:00:00+00:00 https://atuka.com/resource/striatal-histone-modifications-in-models-of-levodopa%e2%80%90induced-dyskinesia/ 2008-04-12T12:00:00+00:00 https://atuka.com/resource/pym50028-a-novel-orally-active-nonpeptide-neurotrophic-factor-inducer-prevents-and-reverses-neuronal-damage-induced-by-mpp-in-mesencephalic-neurons-and-by-mptp-in-a-mouse/ 2008-03-25T12:00:00+00:00 https://atuka.com/resource/receptor%e2%80%90activity-modifying-protein-1-expression-is-increased-in-the-striatum-following-repeated-l%e2%80%90dopa-administration-in-a-6%e2%80%90hydroxydopamine-lesioned-rat-model-of-parkinsons/ 2008-02-01T12:00:00+00:00 https://atuka.com/resource/targeted-delivery-of-an-mecp2-transgene-to-forebrain-neurons-improves-the-behavior-of-female-mecp2-deficient-mice/ 2008-01-25T12:00:00+00:00 https://atuka.com/resource/parkinsons-disease-opportunities-for-novel-therapeutics-to-reduce-the-problems-of-levodopa-therapy/ 2008-01-01T12:00:00+00:00 https://atuka.com/resource/high-frequency-stimulation-or-elevated-k-depresses-neuronal-activity-in-the-rat-entopeduncular-nucleus/ 2007-10-01T12:00:00+00:00 https://atuka.com/resource/levodopa%e2%80%90induced-dyskinesias/ 2007-04-11T12:00:00+00:00 https://atuka.com/resource/striatal-delta-opioid-receptor-binding-in-experimental-models-of-parkinsons-disease-and-dyskinesia/ 2007-01-01T12:00:00+00:00 https://atuka.com/resource/actions-at-sites-other-than-d3-receptors-mediate-the-effects-of-bp897-on-l-dopa-induced-hyperactivity-in-monoamine-depleted-rats/ 2006-11-01T12:00:00+00:00 https://atuka.com/resource/novel-pharmacological-targets-for-the-treatment-of-parkinsons-disease/ 2006-10-01T12:00:00+00:00 https://atuka.com/resource/antiparkinsonian-effects-of-the-novel-d3-d2-dopamine-receptor-agonist-s32504-in-mptp%e2%80%90lesioned-marmosets-mediation-by-d2-not-d3-dopamine-receptors/ 2006-09-21T12:00:00+00:00 https://atuka.com/resource/pharmacological-characterization-of-psychosis%e2%80%90like-behavior-in-the-mptp%e2%80%90lesioned-nonhuman-primate-model-of-parkinsons-disease/ 2006-09-07T12:00:00+00:00 https://atuka.com/resource/dopamine-receptor-agonists-and-levodopa-and-inducing-psychosis-like-behavior-in-the-mptp-primate-model-of-parkinson-disease/ 2006-09-01T12:00:00+00:00 https://atuka.com/resource/a-role-for-vanilloid-receptor-1-trpv1-and-endocannabinnoid-signalling-in-the-regulation-of-spontaneous-and-l-dopa-induced-locomotion-in-normal-and-reserpine-treated-rats/ 2006-09-01T12:00:00+00:00 https://atuka.com/resource/dopamine-receptor-agonists-and-levodopa-and-inducing-psychosis-like-behavior-in-the-mptp-primate-model-of-parkinson-disease-2/ 2006-09-01T12:00:00+00:00 https://atuka.com/resource/phenotype-of-striatofugal-medium-spiny-neurons-in-parkinsonian-and-dyskinetic-nonhuman-primates-a-call-for-a-reappraisal-of-the-functional-organization-of-the-basal-ganglia/ 2006-08-23T12:00:00+00:00 https://atuka.com/resource/translation-of-nondopaminergic-treatments-for-levodopa%e2%80%90induced-dyskinesia-from-mptp%e2%80%90lesioned-nonhuman-primates-to-phase-iia-clinical-studies-keys-to-success-and-roads-to-failure/ 2006-07-27T12:00:00+00:00 https://atuka.com/resource/histamine-h3-receptor-agonists-reduce-l%e2%80%90dopa-induced-chorea-but-not-dystonia-in-the-mptp%e2%80%90lesioned-nonhuman-primate-model-of-parkinsons-disease/ 2006-06-06T12:00:00+00:00 https://atuka.com/resource/%ce%b12-adrenoceptor-mediated-modulation-of-the-release-of-gaba-and-noradrenaline-in-the-rat-substantia-nigra-pars-reticulata/ 2006-03-01T12:00:00+00:00 https://atuka.com/resource/advances-in-the-delivery-of-treatments-for-parkinsons-disease/ 2005-11-01T12:00:00+00:00 https://atuka.com/resource/nondopaminergic-mechanisms-in-levodopa%e2%80%90induced-dyskinesia/ 2005-07-08T12:00:00+00:00 https://atuka.com/resource/differential-effects-of-endocannabinoids-on-3h-gaba-uptake-in-the-rat-globus-pallidus/ 2005-07-01T12:00:00+00:00 https://atuka.com/resource/mptp%e2%80%90induced-models-of-parkinsons-disease-in-mice-and-non%e2%80%90human-primates/ 2005-06-01T12:00:00+00:00 https://atuka.com/resource/a-role-for-endocannabinoids-in-the-generation-of-parkinsonism-and-levodopa%e2%80%90induced-dyskinesia-in-mptp%e2%80%90lesioned-non%e2%80%90human-primate-models-of-parkinsons-disease/ 2005-05-13T12:00:00+00:00 https://atuka.com/resource/subcellular-redistribution-of-the-synapse%e2%80%90associated-proteins-psd%e2%80%9095-and-sap97-in-animal-models-of-parkinsons-disease-and-l%e2%80%90dopa%e2%80%90induced-dyskinesia/ 2005-04-01T12:00:00+00:00 https://atuka.com/resource/alterations-of-striatal-nmda-receptor-subunits-associated-with-the-development-of-dyskinesia-in-the-mptp-lesioned-primate-model-of-parkinsons-disease/ 2005-03-01T12:00:00+00:00 https://atuka.com/resource/a-simple-rodent-assay-for-the-in-vivo-identification-of-agents-with-potential-to-reduce-levodopa-induced-dyskinesia-in-parkinsons-disease/ 2005-02-01T12:00:00+00:00 https://atuka.com/resource/levodopa-induced-dyskinesia-in-parkinsons-disease/ 2004-12-22T12:00:00+00:00 https://atuka.com/resource/topiramate-reduces-levodopa%e2%80%90induced-dyskinesia-in-the-mptp%e2%80%90lesioned-marmoset-model-of-parkinsons-disease/ 2004-12-09T12:00:00+00:00 https://atuka.com/resource/the-nr2b-selective-nmda-receptor-antagonist-cp-101606-exacerbates-l-dopa-induced-dyskinesia-and-provides-mild-potentiation-of-anti-parkinsonian-effects-of-l-dopa-in-the-mptp-lesioned-marmoset-model-o/ 2004-08-01T12:00:00+00:00 https://atuka.com/resource/effects-of-adenosine-a1-dopamine-d1-and-metabotropic-glutamate-5-receptors-modulating-agents-on-locomotion-of-the-reserpinised-rats/ 2004-08-01T12:00:00+00:00 https://atuka.com/resource/selective-blockade-of-d3-dopamine-receptors-enhances-the-anti-parkinsonian-properties-of-ropinirole-and-levodopa-in-the-mptp-lesioned-primate/ 2004-07-01T12:00:00+00:00 https://atuka.com/resource/levetiracetam-interferes-with-the-l-dopa-priming-process-in-mptp-lesioned-drug-naive-marmosets/ 2004-07-01T12:00:00+00:00 https://atuka.com/resource/levetiracetam-potentiates-the-antidyskinetic-action-of-amantadine-in-the-1-methyl-4-phenyl-1236-tetrahydropyridine-mptp-lesioned-primate-model-of-parkinsons-disease/ 2004-03-05T12:00:00+00:00 https://atuka.com/resource/s32504-a-novel-naphtoxazine-agonist-at-dopamine-d3-d2-receptors-ii-actions-in-rodent-primate-and-cellular-models-of-antiparkinsonian-activity-in-comparison-to-ropinirole/ 2004-02-20T12:00:00+00:00 https://atuka.com/resource/levetiracetam-improves-choreic-levodopa-induced-dyskinesia-in-the-mptp-treated-macaque/ 2004-02-01T12:00:00+00:00 https://atuka.com/resource/ropinirole-versus-l-dopa-effects-on-striatal-opioid-peptide-precursors-in-a-rodent-model-of-parkinsons-disease-implications-for-dyskinesia/ 2004-01-01T12:00:00+00:00 https://atuka.com/resource/non%e2%80%90subtype%e2%80%90selective-opioid-receptor-antagonism-in-treatment-of-levodopa%e2%80%90induced-motor-complications-in-parkinsons-disease/ 2003-12-12T12:00:00+00:00 https://atuka.com/resource/cannabinoids-decrease-corticostriatal-synaptic-transmission-via-an-effect-on-glutamate-uptake/ 2003-12-03T12:00:00+00:00 https://atuka.com/resource/sonic-hedgehog-is-a-neuromodulator-in-the-adult-subthalamic-nucleus/ 2003-10-02T12:00:00+00:00 https://atuka.com/resource/increased-striatal-pre-proenkephalin-b-expression-is-associated-with-dyskinesia-in-parkinsons-disease/ 2003-10-01T12:00:00+00:00 https://atuka.com/resource/novel-antiepileptic-drug-levetiracetam-decreases-dyskinesia-elicited-by-l%e2%80%90dopa-and-ropinirole-in-the-mptp%e2%80%90lesioned-marmoset/ 2003-08-21T12:00:00+00:00 https://atuka.com/resource/fipamezole-jp%e2%80%901730-is-a-potent-%ce%b12-adrenergic-receptor-antagonist-that-reduces-levodopa%e2%80%90induced-dyskinesia-in-the-mptp%e2%80%90lesioned-primate-model-of-parkinsons-disease/ 2003-05-06T12:00:00+00:00 https://atuka.com/resource/presymptomatic-compensation-in-parkinsons-disease-is-not-dopamine-mediated/ 2003-04-01T12:00:00+00:00 https://atuka.com/resource/cb-cannabinoid-receptor-signalling-in-parkinsons-disease/ 2003-02-01T12:00:00+00:00 https://atuka.com/resource/5%e2%80%90hydroxytryptamine-5%e2%80%90ht-serotonin-and-parkinsons-disease-opportunities-for-novel-therapeutics-to-reduce-the-problems-of-levodopa-therapy/ 2002-11-01T12:00:00+00:00 https://atuka.com/resource/effects-of-cb1-cannabinoid-receptor-modulating-compounds-on-the-hyperkinesia-induced-by-high%e2%80%90dose-levodopa-in-the-reserpine%e2%80%90treated-rat-model-of-parkinsons-disease/ 2002-10-10T12:00:00+00:00 https://atuka.com/resource/stimulation-of-cannabinoid-receptors-reduces-levodopa%e2%80%90induced-dyskinesia-in-the-mptp%e2%80%90lesioned-nonhuman-primate-model-of-parkinsons-disease/ 2002-07-25T12:00:00+00:00 https://atuka.com/resource/protection-of-striatal-neurons-by-joint-blockade-of-d1-and-d2-receptor-subtypes-in-an-in-vitro-model-of-cerebral-hypoxia/ 2002-07-01T12:00:00+00:00 https://atuka.com/resource/striatal-ampa-receptor-binding-is-unaltered-in-the-mptp-lesioned-macaque-model-of-parkinsons-disease-and-dyskinesia/ 2002-03-01T12:00:00+00:00 https://atuka.com/resource/characterisation-of-striatal-nmda-receptors-involved-in-the-generation-of-parkinsonian-symptoms-intrastriatal-microinjection-studies-in-the-6%e2%80%90ohda%e2%80%90lesioned-rat/ 2002-01-16T12:00:00+00:00 https://atuka.com/resource/randomised-double%e2%80%90blind-placebo%e2%80%90controlled-trial-to-assess-the-potential-of-cannabinoid-receptor-stimulation-in-the-treatment-of-dystonia/ 2002-01-01T12:00:00+00:00 https://atuka.com/resource/cannabinoids-reduce-levodopa-induced-dyskinesia-in-parkinsons-disease-a-pilot-study/ 2001-12-01T12:00:00+00:00 https://atuka.com/resource/antiparkinsonian-action-of-a-%ce%b4-opioid-agonist-in-rodent-and-primate-models-of-parkinsons-disease/ 2001-11-01T12:00:00+00:00 https://atuka.com/resource/relationship-between-the-appearance-of-symptoms-and-the-level-of-nigrostriatal-degeneration-in-a-progressive-1-methyl-4-phenyl-1236-tetrahydropyridine-lesioned-macaque-model-of-parkinsons-disease/ 2001-09-01T12:00:00+00:00 https://atuka.com/resource/%ce%bc-and-%ce%b4-opioid-receptor-antagonists-reduce-levodopa-induced-dyskinesia-in-the-mptp-lesioned-primate-model-of-parkinsons-disease/ 2001-09-01T12:00:00+00:00 https://atuka.com/resource/pathophysiology-of-levodopa-induced-dyskinesia-potential-for-new-therapies/ 2001-08-01T12:00:00+00:00 https://atuka.com/resource/neural-mechanisms-underlying-peak%e2%80%90dose-dyskinesia-induced-by-levodopa-and-apomorphine-are-distinct-evidence-from-the-effects-of-the-alpha2-adrenoceptor-antagonist-idazoxan/ 2001-07-01T12:00:00+00:00 https://atuka.com/resource/striatal-cannabinoid-cb1-receptor-mrna-expression-is-decreased-in-the-reserpine-treated-rat-model-of-parkinsons-disease/ 2001-06-01T12:00:00+00:00 https://atuka.com/resource/upregulation-of-striatal-preproenkephalin-gene-expression-occurs-before-the-appearance-of-parkinsonian-signs-in-1-methyl-4-phenyl-1236-tetrahydropyridine-monkeys/ 2001-04-01T12:00:00+00:00 https://atuka.com/resource/structures-outside-the-basal-ganglia-may-compensate-for-dopamine-loss-in-the-presymptomatic-stages-of-parkinsons-disease/ 2001-04-01T12:00:00+00:00 https://atuka.com/resource/pallidal-border-cells-an-anatomical-and-electrophysiological-study-in-the-1-methyl-4-phenyl-1236-tetrahydropyridine-treated-monkey/ 2001-02-01T12:00:00+00:00 https://atuka.com/resource/5-ht2c-receptor-binding-is-increased-in-the-substantia-nigra-pars-reticulata-in-parkinsons-disease/ 2000-11-01T12:00:00+00:00 https://atuka.com/resource/a-common-signaling-pathway-for-striatal-nmda-and-adenosine-a2areceptors-implications-for-the-treatment-of-parkinsons-disease/ 2000-10-15T12:00:00+00:00 https://atuka.com/resource/antiparkinsonian-actions-of-ifenprodil-in-the-mptp-lesioned-marmoset-model-of-parkinsons-disease/ 2000-09-01T12:00:00+00:00 https://atuka.com/resource/enhanced-levels-of-endogenous-cannabinoids-in-the-globus-pallidus-are-associated-with-a-reduction-in-movement-in-an-animal-model-of-parkinsons-disease/ 2000-07-01T12:00:00+00:00 https://atuka.com/resource/5-ht2c-receptor-antagonists-enhance-the-behavioural-response-to-dopamine-d1-receptor-agonists-in-the-6-hydroxydopamine-lesioned-rat/ 2000-06-01T12:00:00+00:00 https://atuka.com/resource/nmda-receptors-in-the-basal-ganglia/ 2000-05-01T12:00:00+00:00 https://atuka.com/resource/the-adrenergic-receptor-agonist-clonidine-potentiates-the-anti%e2%80%90parkinsonian-action-of-the-selective-%ce%ba%e2%80%90opioid-receptor-agonist-enadoline-in-the-monoamine%e2%80%90depleted-rat/ 1999-12-01T12:00:00+00:00 https://atuka.com/resource/the-2-adrenergic-receptor-antagonist-idazoxan-reduces-dyskinesia-and-enhances-anti-parkinsonian-actions-ofl-dopa-in-the-mptp-lesioned-primate-model-of-parkinsons-disease/ 1999-09-01T12:00:00+00:00 https://atuka.com/resource/control-of-glutamate-release-by-calcium-channels-and-%ce%ba%e2%80%90opioid-receptors-in-rodent-and-primate-striatum/ 1999-05-01T12:00:00+00:00 https://atuka.com/resource/effect-of-repeatedl-dopa-bromocriptine-or-lisuride-administration-on-preproenkephalin-a-and-preproenkephalin-b-mrna-levels-in-the-striatum-of-the-6-hydroxydopamine-lesioned-rat/ 1999-02-01T12:00:00+00:00 https://atuka.com/resource/antiparkinsonian-actions-of-blockade-of-nr2b-containing-nmda-receptors-in-the-reserpine-treated-rat/ 1999-01-01T12:00:00+00:00 https://atuka.com/resource/adjuncts-to-dopamine-replacement-a-pragmatic-approach-to-reducing-the-problem-of-dyskinesia-in-parkinsons-disease/ 1998-11-01T12:00:00+00:00 https://atuka.com/resource/3h%e2%80%902%e2%80%90deoxyglucose-uptake-study-in-mutant-dystonic-hamsters-abnormalities-in-discrete-brain-regions-of-the-motor-system/ 1998-07-01T12:00:00+00:00 https://atuka.com/resource/characterization-of-enhanced-behavioral-responses-tol-dopa-following-repeated-administration-in-the-6-hydroxydopamine-lesioned-rat-model-of-parkinsons-disease/ 1998-06-01T12:00:00+00:00 https://atuka.com/resource/behavioral-effects-of-5-ht2creceptor-antagonism-in-the-substantia-nigra-zona-reticulata-of-the-6-hydroxydopamine-lesioned-rat-model-of-parkinsons-disease/ 1998-05-01T12:00:00+00:00 https://atuka.com/resource/topographical-organization-of-opioid-peptide-precursor-gene-expression-following-repeated-apomorphine-treatment-in-the-6-hydroxydopamine-lesioned-rat/ 1998-04-01T12:00:00+00:00 https://atuka.com/resource/kappa%e2%80%90opioid-receptor-agonists-increase-locomotor-activity-in-the-monoamine%e2%80%90depleted-rat-model-of-parkinsonism/ 1998-03-01T12:00:00+00:00 https://atuka.com/resource/the-cannabinoid-receptor-agonist-win-55212-2-reduces-d2-but-not-d1-dopamine-receptor-mediated-alleviation-of-akinesia-in-the-reserpine-treated-rat-model-of-parkinsons-disease/ 1997-11-01T12:00:00+00:00 https://atuka.com/resource/novel-approaches-to-the-symptomatic-treatment-of-parkinsonian-syndromes/ 1997-08-01T12:00:00+00:00 https://atuka.com/resource/enhancement-of-the-behavioral-response-to-apomorphine-administration-following-repeated-treatment-in-the-6-hydroxydopamine-lesioned-rat-is-temporally-correlated-with-a-rise-in-striatal-preproenkephali/ 1997-04-01T12:00:00+00:00 https://atuka.com/resource/paradoxical-action-of-the-cannabinoid-win-55212%e2%80%902-in-stimulated-and-basal-cyclic-amp-accumulation-in-rat-globus-pallidus-slices/ 1997-04-01T12:00:00+00:00 https://atuka.com/resource/modulation-of-neurotransmission-by-cannabinoids-in-the-basal-ganglia/ 1997-02-01T12:00:00+00:00 https://atuka.com/resource/ionotropic-glutamate-receptors-and-nitric-oxide-synthesis-in-the-rat-striatum/ 1996-12-01T12:00:00+00:00 https://atuka.com/resource/new-treatments-for-movement-disorders/ 1996-10-01T12:00:00+00:00 https://atuka.com/resource/activation-of-the-cannabinoid-receptor-by-%ce%b49-tetrahydrocannabinol-reduces-%ce%b3-aminobutyric-acid-uptake-in-the-globus-pallidus/ 1996-07-01T12:00:00+00:00 https://atuka.com/resource/modulation-of-gaba-transmission-by-diazoxide-and-cromakalim-in-the-globus-pallidus-implications-for-the-treatment-of-parkinsons-disease/ 1996-05-01T12:00:00+00:00 https://atuka.com/resource/normethylclozapine-potentiates-the-action-of-quinpirole-in-the-6-hydroxydopamine-lesioned-rat/ 1996-04-01T12:00:00+00:00 https://atuka.com/resource/modulation-of-gabaergic-transmission-in-the-globus-pallidus-by-the-synthetic-cannabinoid-win-55212-2/ 1996-04-01T12:00:00+00:00 https://atuka.com/resource/potential-of-opioid-antagonists-in-the-treatment-of-levodopa-induced-dyskinesias-in-parkinsons-disease/ 1996-01-01T12:00:00+00:00 https://atuka.com/resource/modulation-of-glutamate-release-by-a-%ce%ba-opioid-receptor-agonist-in-rodent-and-primate-striatum/ 1995-07-01T12:00:00+00:00 https://atuka.com/resource/functional-implications-of-kappa-opioid-receptor-mediated-modulation-of-glutamate-transmission-in-the-output-regions-of-the-basal-ganglia-in-rodent-and-primate-models-of-parkinsons-disease/ 1995-06-01T12:00:00+00:00 https://atuka.com/resource/neurochemical-and-behavioural-investigations-of-the-nmda-receptor-associated-glycine-site-in-the-rat-striatum-functional-implications-for-treatment-of-parkinsonian-symptoms/ 1995-05-01T12:00:00+00:00 https://atuka.com/resource/metabotropic-glutamate-receptor-agonists-inhibit-endogenous-glutamate-release-from-rat-striatal-synaptosomes/ 1995-04-01T12:00:00+00:00